logo-loader
LSE:RENE FRA:RQE1

ReNeuron Group PLC

 Receive alerts
Market:
LSE
Market Cap:
£42.81 m
Price
134.50 GBX
Change
4.26%
52 weeks high
342.00
52 weeks low
29.50
01.03

Director Interviews

In brief

ReNeuron is a leading, clinical-stage stem cell business.  Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.

In brief Deep dive Research Latest news Insight Interviews

Deep dive We explore the investor case for growth companies

ReNeuron progresses as it gathers more data for developing treatments
dna strand

Snapshot

  • Developer of stem cell technologies
  • Has two clinical stage technologies
  • Stroke treatment in Phase IIb trials
Open Deep dive

Latest news

ReNeuron to present data showing “significant advance” of CTX treatment

on 23/10/19

ReNeuron cell-based treatment hailed by leading non-profit group funding...

on 14/10/19

ReNeuron hails "clear signal" from retinitis pigmentosa trials

on 8/10/19

ReNeuron remains in talks with potential partners

on 10/9/19

ReNeuron hails heavy hitting new appointments to scientific advisory board

on 21/8/19

ReNeuron inks University of Cardiff collaboration

on 14/8/19

ReNeuron granted international patents over cell technology

on 16/7/19

ReNeuron creates role of business development and alliance director as deals...

on 13/7/19

Interviews

ReNeuron Group PLC - 'All systems go' for ReNeuron's retinitis pigmentosa programme as it looks to follow-up studies Health Full interview: 'All systems go' for ReNeuron's retinitis pigmentosa programme as it looks to follow-up studies
on 7/10/19
1562933195_RENEURON_july_12.jpg Health ReNeuron makes key business development hire as it looks to build on licensing deals
on 12/7/19
1558707585_RENEURON_HUNT_may_8.jpg Health ReNeuron Group Plc - Proactive One2One Investor Forum May 2019
on 25/5/19
1558103415_EVENTS_THOMAS_MAY_17.jpg Retail & consumer Lookahead to Proactive Investors evening event Thursday May 23
on 17/5/19
View all